BackReata Pharmaceuticals Overview

Reata Pharmaceuticals Long Term Debt

Track Reata Pharmaceuticals's long-term debt ($160M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$163.55M

Peer trimmed avg / median

Loading

Reata Pharmaceuticals Long Term Debt History

Loading

Reata Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Reata Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Reata Pharmaceuticals (RETA) FAQ

Reata Pharmaceuticals (RETA) currently reports a long-term debt of $160M as of June 2023. In the prior-year period, the figure was $0. Use the charts on this page to explore Reata Pharmaceuticals's long-term debt history and peer comparisons.

Reata Pharmaceuticals's long-term debt changed from $0 to $160M (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reata Pharmaceuticals reported $160M in long-term debt as of June 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $160M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Reata Pharmaceuticals, and consider following RETA for alerts when major investors trade the stock.

Reata Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $160M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RETA with unrelated industries.